BACKGROUND
Acute mixed bipolar/major depression is relatively frequent, yet quantitative information about its pharmacological management is relatively scant, warranting network meta-analysis (NMA) of comparative efficacy/response/acceptability of pharmacological interventions accounting for dose effects across differe...
M. Fornaro, C. Di Lorenzo, Nicolas A. Nunez et al.· Journal of Affective Disorde...· 0 citations
Individuals with bipolar disorder (BD) face elevated rates of chronic kidney disease (CKD) and premature mortality yet remain underrepresented in cardiorenal trials. Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have established renoprotective ben...
Balwinder Singh, Feyza Yaylaci, Hossam M. Ali et al.· Journal of Affective Disorde...· 0 citations
Rigorous RCTs with standardized protocols, larger sample sizes, uniform dosing, and systematic biomarker investigations are needed to clarify ketamine’s neurochemical mechanism and optimize ketamine’s clinical application in treatment-resistant depression.
Balwinder Singh, Hossam M. Ali, Alessandro Miola et al.· Neuropsychopharmacology· 0 citations
Addressing the multifaceted diagnostic and pharmacotherapeutic challenges of OABD through dedicated age-specific clinical trials, comparative effectiveness studies, systematic evaluation of deprescribing strategies, and enhanced clinician awareness will be fundamental to improve outcomes for this understudied and expan...